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Abstract
Background: Numerous technical modifications to radical prostatectomy have been proposed. Such modifications
are likely to lead to only slight improvements in outcomes. Although small differences would be worthwhile, an
appropriately powered randomized trial would need to be very large, and thus of doubtful feasibility given the
expense, complexity and regulatory burden of contemporary clinical trials. We have proposed a novel
methodology, the clinically-integrated randomized trial, which dramatically streamlines trial procedures in order to
reduce the marginal cost of an additional patient towards zero. We aimed to determine the feasibility of
implementing such a trial for radical prostatectomy.
Methods: Patients undergoing radical prostatectomy as initial treatment for prostate cancer were randomized in a
factorial design to involvement of the fascia during placement of the anastomotic sutures, urethral irrigation, both
or neither. Endpoint data were obtained from routine clinical documentation. Accrual and compliance rates were
monitored to determine the feasibility of the trial.
Results: From a total of 260 eligible patients, 154 (59%) consented; 56 patients declined to participate, 20 were not
approached on recommendation of the treating surgeon, and 30 were not approached for logistical reasons.
Although recording by surgeons of the procedure used was incomplete (~80%), compliance with randomization
was excellent when it was recorded, with only 6% of procedures inconsistent with allocation. Outcomes data was
received from 71% of patients at one year. This improved to 83% as the trial progressed.
Conclusions: A clinically-integrated randomized trial was conducted at low cost, with excellent accrual, and
acceptable compliance with treatment allocation and outcomes reporting. This demonstrates the feasibility of the
methodology. Improved methods to ensure documentation of surgical procedures would be required before wider
implementation.
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A radical prostatectomy (RP) is one of the most com-
plex operations performed by urologists. The ideal out-
come of a RP is complete removal of the cancer with no
sunsequent recurrence, minimal blood loss, no serious
perioperative complications and complete recovery of
erectile and urinary function. No surgeon achieves such
results uniformly and it appears likely that results are
highly sensitive to fine details of surgical technique.
Considerable recent data suggests that outcomes of RP
are indeed surgeon dependent. The largest body of evi-
dence comes from what are known as “volume out-
come” studies: typically, an administrative database, such
as Medicare, is searched and surgical outcomes recorded
along with details of the number of procedures con-
ducted by a surgeon in the previous 12 months. It has
been reported that surgeons with a higher yearly case-
load have better outcomes [1-3] and that there is greater
than chance variation between surgeons even adjusting
for volume [1,2,4].
It seems reasonable to suppose that, if the results of
RP differ by surgeon, there must be identifiable aspects
of surgical technique that affect outcome. The urologic
literature is replete with modifications to the contem-
porary standard RP. As some illustrative examples,
investigators have recommended modifications such as
avoidance of countertraction during nerve sparing [5];
transverse camera port incision for robotically-assisted
RP [6]; lateral view dissection of the prostato-urethral
junction during laparoscopic RP [7]; posterior recon-
struction of the rhabdosphincter [8]; division of the dor-
sal venous complex before rather than after suture
ligation [9].
We have previously argued that the increasing cost,
complexity and regulatory burden of contemporary clin-
ical trials makes it infeasible that these sorts of modifi-
cations could be subject to randomized comparison
[10]. For example, imagine that avoidance of counter-
traction during nerve sparing could improve rates of
erectile function from 50% to 55%, a small but highly
worthwhile benefit given that it results from a minor
surgical modification. A trial with sufficient power
detect this effect size would require more than 3000
patients. Given that a typical randomized trial costs over
$5000 per patient [11], the trial budget might approach
$20 million. It is highly unlikely that any funder would
consider such a trial.
We have proposed a novel methodology - the clini-
cally-integrated randomized trial - in an effort to drama-
tically decrease trial costs and therefore enlarge the
number of clinical questions that can be addressed by
randomization. The key aspect of our methodology is
that the clinical experience of the patient and doctor is
virtually indistinguishable whether or not the patient is
randomized, primarily because trial endpoints are
obtained from routine clinical data. Trial patients go
through informed consent procedures, and certain
aspects of care, such as modifications to the surgical
technique used, are determined by randomization rather
than being at the discretion of the doctor. Otherwise,
there are no obvious differences between the clinical
care, follow-up, payment and documentation require-
ments between patients who do and do not participate
in the trial. The lack of trial specific procedures entails
the marginal cost of putting an additional patient on
trial becomes close to zero [10].
Here we report a feasibility study of clinically-inte-
grated randomized trial of modifications to RP
(NCT00928850). Our primary objective was to deter-
mine the acceptability of the trial to surgeons and
patients, defined in terms of accrual rates and
compliance.
Methods
This was a single center, feasibility study of a rando-
mized trial, approved by the Institutional Review Board
of Memorial Sloan Kettering Cancer Center (MSKCC)
in accordance with the Helsinki declaration (protocol
number 09-051). The study took place in the urology
clinics of MSKCC in New York, NY from July 2009 to
April 2010. Eligible patients were those scheduled for
radical prostatectomy for the treatment of prostate can-
cer with one of the consenting surgeons at MSKCC.
Exclusion criteria was prior treatment for prostate can-
cer (radiation, hormonal therapy, chemotherapy or focal
therapy).
Patients were randomized to irrigation, involvement of
the fascia during placement of the anastomotic sutures,
both or neither. A full description of each technique is
given in additional file 1. In brief, the irrigation proce-
dure involved irrigating the Foley catheter with 60 cc of
sterile water before it is removed. The irrigation fluid
was then suctioned away. The comparison of anastomo-
tic suture placement concerned the part of the RP after
division of the dorsal venous complex. After the initial
placement of the anastomotic suture through the ure-
thra, patients to were randomized to have a second bite
taken deeply into the lateral pelvic fascia vs. no second
bite.
Patients were randomized using the Clinical Research
Database, a secure computer randomization system that
ensures full allocation concealment. Blocks were of ran-
domly selected length, stratified by treating surgeon (n
= 6) and preoperative risk: low risk (PSA < 10 and
biopsy Gleason ≤ 6), high risk (PSA > 20 or biopsy
Gleason ≥ 8 or clinical stage ≥ T2c) or intermediate risk
(not high or low risk). Patients were informed of their
treatment allocation if they requested it.
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Page 2 of 8The primary endpoints were the proportion of
patients accured and the accrual rate. The secondary
objective was to determine surgeon compliance with
allocation and outcomes recording. We choose a sample
size of 180. Based on an expected accrual rate of 50-
65% of eligible patients, the 95% Poisson confidence
interval around 180 events in a unit period is 155-208
and the 95% exact binomial confidence interval for a
proportion of 180 patients (e.g. data completion) is at
most ± 8%.
In addition, we summarized the proportion of patients
with eligible post-operative functional assessments, col-
lected as part of routine clinical practice. Patients were
defined as functional if they did not use routinely need
continence pads in everyday life. We converted the
time-to-event data into binary variables for the out-
comes of 6 month and 12 month function. For 6 (12)
month outcomes, patients who regained function before
7 (14) months after surgery were considered to have
regained function; patients who were not functional
after 5 (10) months and who did not regain function
between 5 and 7 (10 and 14) months were considered
non-functional. All analyses were conducted using Stata
11.0 (Stata Corp., College Station, Tx).
Results
The trial was stopped shortly before achieving accrual
goals when the Urology Service at Memorial Sloan-Ket-
tering Cancer Center placed a temporary moratorium
on all clinical trial consents due to staffing changes. Out
of a total of 260 eligible patients, 154 (59%; 95% C.I.
53%, 65%) consented. Of the remainder, 56 patients
declined to participate and 20 were not approached on
recommendation of the treating surgeon. Thirty patients
were not approached for logistical reasons, such as staff
availability or patient time constraints (Figure 1).
Figure 1 Summary of patient consent and randomization.
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we evaluated the accrual rate using the last 3 months of
the study (January - March 2010), when all clinics were
actively consenting patients. A total of 111 eligible
patients were seen during this time, of which 67 were
consented for a consent rate of 60%. Based on these
numbers, we expect to accrue approximately 270 patients
per year (95% CI: 208, 340). If we further assume that,
with further experience of trial management and liberali-
z a t i o no ft h ee l i g i b i l i t yc r i t e r i a-i faf u t u r es t u d yd i dn o t
exclude patients for prior treatment - an accrual rate of
300 per year would seem a reasonable target.
There was wide variation in the consent and accrual
rate across clinics. We piloted the trial in seven clinics.
Table 1 Baseline characteristics of the study sample.
No fascial suturing (n = 77) Fascial suturing (n = 77)
Age 61.1 (57.8, 64.1) 61.3 (57.7, 65.3)
PSA at diagnosis 5.19 (3.66, 6.59) 5.17 (3.76, 6.59)
Clinical stage T1 57 (74%) 52 (68%)
Clinical stage T2a 12 (16%) 14 (18%)
Clinical stage T2b+ 8 (10%) 11 (14%)
Biopsy Gleason grade
6 28 (36%) 29 (38%)
7 42 (55%) 40 (52%)
8 7 (9%) 8 (10%)
Patients undergoing surgery n = 74 n = 77
Pathologic Gleason grade
1
6 10 (14%) 8 (11%)
7 57 (77%) 59 (79%)
8 7 (9%) 8 (11%)
Positive surgical margins
2 11 (15%) 9 (12%)
Seminal vesicle invasion 5 (7%) 7 (9%)
Extraprostatic extension 35 (47%) 36 (48%)
Lymph node invasion 6 (8%) 6 (8%)
Irrigation (n = 77) No irrigation (n = 77)
Age 60.3 (55.9, 65.2) 59.9 (56.1, 64.2)
PSA at diagnosis 4.95 (3.72, 6.90) 4.95 (3.66, 6.90)
Clinical stage T1 44 (57%) 49 (64%)
Clinical stage T2a 18 (23%) 16 (21%)
Clinical stage T2b+ 15 (19%) 12 (16%)
Biopsy Gleason grade
6 30 (39%) 29 (38%)
7 32 (42%) 34 (44%)
8 15 (19%) 14 (18%)
Patients undergoing surgery n = 74 n = 76
Pathologic Gleason grade
1
6 9 (12%) 11 (15%)
7 59 (78%) 57 (76%)
8 8 (11%) 7 (9%)
Positive surgical margins
2 11 (14%) 13 (17%)
Seminal vesicle invasion 10 (13%) 8 (11%)
Extraprostatic extension 35 (45%) 34 (45%)
Lymph node invasion 7 (9%) 7 (9%)
All values are median (IQR) or frequency (proportion).
1. Grade not assess in one patient due to neoadjuvant therapy
2. One patient missing data
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Page 4 of 8In the last three months of the trial, the consent rates
across clinics ranged from 33% to 95% and the number
of consents from 0 (a clinic where no eligible patients
presented) to 21.
Table 1 summarizes the baseline characteristics of
included patients. The cohort is typical of the trend
towards treatment of higher risk patients following the
increasing reliance on active surveillance at academic
centers.
Of the 154 patients randomized, 151 received radical
prostatectomy. Figure 1 summarizes the number of
patients who were treated according to their randomiza-
tion. A non-trivial number of patients, around 1 in 5,
were missing data on the actual treatment received.
Nonetheless, in patients for whom treatment was
recorded, this was inconsistent with allocation for only
6% (95% C.I. 2%, 10%), suggesting good surgeon
compliance.
We explored predictors of protocol deviations, either
in terms of failure to document procedures or differ-
ences between randomized and received procedure.
There were no statistically significant associations with
any patient characteristics (stage, grade, PSA or age) or
treatment allocation (relative risk for irrigation of 0.64;
95% C.I. 0.37, 1.10; p = 0.12; relative risk for fascial
suturing of 0.78; 95% C.I. 0.45, 1.40; p = 0.4). There
were, however, clear differences between surgeons (p =
0.021). One surgeon had clearly lower documentation
rates (61% vs. 79%); a different surgeon was responsible
for 4 out of the 7 cases where treatment was inconsis-
tent with allocation.
Table 2 summarizes the number of patients with cur-
rently available functional outcome data. An acceptable
proportion of patients had eligible assessments at 6
(65%; 95% C.I. 57%, 72%) and 12 months (71%; 95% C.I.
63%, 78%). Furthermore, we expect some of the patients
currently with no assessments or a last assessment
before the eligibility window to return for an assessment
in the future, potentially increasing the number of
patients with eligible functional outcome data. We did
not find statistically significant associations between
missing data and any patient characteristics or treatment
allocation (relative risk for irrigation 0.99; 95% C.I. 0.60,
1.60; p = 1; relative risk for suturing 0.88; 95% C.I. 0.53,
1.40; p = 0.6). However, again there were marked differ-
ences between surgeons (p = 0.034). The total number
of patients with missing documentation of procedure or
missing outcome data was 65 (43%; 95% C.I. 36%, 51%).
Although we did not expect to find important differ-
ences between groups in this underpowered feasibility
study, we did conduct exploratory analyses of outcome
by group. A total of 13 patients experienced a biochem-
ical recurrence, 8 among those randomized to receive
urethral irrigation and 5 among those randomized not to
receive the intervention (hazard ratio 1.6; 95% C.I. 0.51,
4.81). Continence at one year was reported by 54 out of
56 patients randomized to fascial involvement in the pla-
cing of the anastomotic sutures (96%) compared to 45
out of 51 in patients randomized to have no fascial sutur-
ing (88%; risk difference 8%, 95% C.I., -2%, 18%).
Discussion
We have demonstrated the feasibility of a clinically-inte-
grated randomized trial. First, the trial was conducted at
extremely low cost. With the exception of protocol writ-
ing and data analysis, and start-up meetings with sur-
geons and on-going trial monitoring, the only non-
trivial expenditure of time or money was for consenting
patients. Clinic staff could readily identify and flag eligi-
ble patients with a negligible expenditure of effort. We
found that surgeons could usually explain the idea
behind the trial to patients in 2 - 3 minutes. Consent
paperwork was handled by research assistants concur-
rent with other standard consents, such as for tissue use
protocols. The process of randomization - stratification,
faxing of consent documents, and communication of
results to surgical fellows - took research assistants 5 -
10 minutes per patient. Trial data were directly down-
loaded from the clinical database by the trial statistician.
In comparison with a traditional trial, our study avoided
many costs - including those for research assistants to
f o l l o wp a t i e n t so v e rt i m ea sw e l la st h ec o s to fd a t a
abstraction and data entry - but did not incur any addi-
tional costs, as all aspects of the clinically-integrated
trial (e.g. consent, start up meetings) are also a neces-
sary part of more traditional designs.
Second, randomization did indeed become a routine
part of clinical practice, with approximately 80% of
patients being approached and close to 75% of those
agreeing to participate. Third, we were able to obtain
outcome data on a high proportion of patients, despite
there being no attempt whatsoever to follow trial
patients differently outside of routine clinical care.
Table 2 Summary of functional outcomes assessment for
patients on protocol 09-051 who received radical
prostatectomy (n = 151).
Continent
6
months
12
months
Yes 68 99
No 30 8
First assessment after window* & functional 20
Last assessment before window* & not
functional
38 31
No assessments 13
*window is defined as 10-14 months for 12 month assessment and 5-7
months for 6 month assessment.
Vickers et al. Trials 2012, 13:23
http://www.trialsjournal.com/content/13/1/23
Page 5 of 8Various lessons were learned during study start up
and implementation. Before the first patient was rando-
mized, trial staff spent time with clinic patients discuss-
ing how different ways of describing the trial would
affect the degree of comfort that they would feel in par-
ticipating. The major concern of patients concerned
whether they might receive substandard care if they
took part. Patients appeared particularly averse to
descriptions of the trial suggesting that treatment would
be given at random. Accordingly, in both the written
consent form (see additional file 2) and in oral presenta-
tions of the trial, the “uncertainty principle”[12] was
stressed. Patients were told that surgeons would always
use their clinical judgment, and would choose the treat-
ment approach that would lead to the best outcome; if
and only if the surgeon was genuinely unsure of which
approach to take would the randomized allocation be
accessed. Discussions with patients also revealed that it
was critical that the trial first be introduced to them by
their surgeon; being approached by a research assistant
or even clinical fellow (a surgeon in training working
with the attending surgeon) would lead patients to sus-
pect that their surgeon was not fully confident about
the trial.
Given the critical role that administrative clinic staff
played in identifying eligible patients and bringing them
to the attention of surgeons, we expended considerable
effort involving clinical staff in trial start up (see addi-
tional file 3). As each surgeon ran clinics in a slightly
different way, we relied on clinic staff to suggest trial
procedures. For example, one clinic nurse suggested
including a brightly colored reminder notice in the case
file given to the surgeon before entering the consulta-
tion room. Involving staff in this way increased “owner-
ship” i nt h et r i a la n dp r o v i d e di n c e n t i v e sf o rh i g h
accrual rates. To complement this approach, we tracked
consent rates for different clinics, bringing the results to
the attention of surgeons and their clinic staff.
Surgical fellows play a key role in the everyday run-
ning of clinics, in most instances, being the first doctor
who sees a patient considering surgery. Working closely
with the surgical fellows therefore also became a key
aspect of efficient trial management. Indeed, we often
saw large changes in accrual rates within a particular
clinic as fellows rotated. We were keen to emphasize
the importance and novelty of the trial and to appeal to
fellows’ commitment to evidence-based medicine.
That said, encouragement of surgeons, surgical fellows
and non-medical clinic staff may have been unproduc-
tive without the full support of the surgical leadership of
the hospital. The co-principal investigator was the chair
of the Department of Surgery. It is difficult to imagine
that the trial would have accrued without this enthusias-
tic endorsement.
Nonetheless, further attention to routine systems of
data gathering will be required before the methodology
can be optimized. Recording of compliance with rando-
mization was missing in about 20% of cases, and so
clearly additional procedures need to be established to
ensure this key aspect of documentation. In particular,
we propose adding easy to use “tick boxes” in the opera-
tive record. Doing so would not only ease documenta-
tion, but would allow the study team to conduct on-
going monitoring of compliance both with documenta-
tion and with treatment allocation. This would allow
identification of surgeons with poor compliance and sui-
table intervention.
Recording of patient outcome, while adequate, was
also less than perfect. Since the protocol was opened,
we have moved to entirely electronic reporting of
patient outcomes, via emails to patients at home or
iPads in the clinic. To assess how this new system
affects patient reporting, we studied all patients treated
by radical prostatectomy between January 2010 (towards
the end of the trial, when the electronic recording was
fully implemented) and October 2010 (to allow all
patients to have 14 months of follow-up). During this
period, 599 patients were treated and we obtained data
for urinary function at one year from 498, a data com-
pletion rate of 83%. We are also in the process of imple-
menting a system that provides feedback to patients on
the basis of their answers, for example, recommending
referral to a voiding dysfunction specialist to patients
who report urinary dysfunction [13]. We anticipate that
improving use of patient-reported outcomes in clinical
practice - an approach that has been shown to improve
doctor-patient communication [14] and decrease symp-
tom intensity [15] - will also increase data completion
rates in subsequent clinically-integrated trials. We also
recommend the use of sensitivity analysis in any subse-
quent, fully powered trial, to determine whether missing
data may have influenced the strength or direction of
results.
That said, we are confident that the rates of data com-
pletion we report here - even if suboptimal - fully justi-
fies the clinically-integrated randomized trial
methodology. With respect to missing documentation
on surgical approaches, we have no reason to believe
that missing data reflected treatment choices: in discus-
sion with clinicians, it seem e dt h a td o c u m e n t a t i o nf a i l -
ures were inadvertent. Naturally, we cannot entirely rule
out bias with respect to documentation. This is partly a
function of having relatively wide confidence intervals
around the estimates of differences between groups. Per-
haps more importantly, the possibility of bias may
change depending on the surgeons and comparison
involved. For example, it might be that in some other
implementation of the clinically-integrated trial
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ferences might attempt to subvert the trial by selective
documentation. As such, careful monitoring of docu-
mentation rates, and statistical comparisons of patients
with and without documentation of the procedure used,
will be important in any clinically-randomized trial.
With respect to missing outcome data, we saw no evi-
dence that this varied by patient characteristics. To
determine whether our 29% rate of missing data is in
anyway extreme or outlying in the context of rando-
mized trials in general, we examined typical rates in
other fields. In two studies examining reports in major
medical journals, about 20% of trials had a rate of miss-
ing data more than 20%[16,17]. However, rates do vary
depending on the patient group and length of follow-up:
mean 30% at one year in weight loss research [18];
mean 37% for short-term studies of depression [19];
20% of rheumatology trials had more than 30% missing
data [20]. It is of note that in each of these research
areas, the likelihood of bias due to missing data is far
higher than for the current trial. There are obvious rea-
sons why drop-out would be associated with inefficacy
in depression or weight-loss trials and with medication
side-effects in rheumatology trials. In contrast, it is hard
t os e eh o wap a t i e n t ’s allocation or continence status
would affect his propensity to continue with clinical fol-
low-up. In contrast, patients return for follow-up after
radical prostatectomy to check for recurrence. If a
patient with urinary dysfunction was more or less likely
to return for a cancer check, then the mechanism for
this is far less obvious than how continuing depression
would affect a patient’s willingness to continue on a
drug study.
As such, missing outcome data is largely an issue of
decreased sample size. A more traditional approach to
the randomized trial, where patients would complete
protocol-specific questionnaires under close monitoring
by study staff, might well have a higher overall rate of
data completion. Given the expense of such trials, and
the lowered patient acceptance of and recruitment to
studies that involve additional reporting burden, the
overall number of patients providing data would likely
be higher with a clinically-integrated trial approach.
This might also be explained in a “value of information”
c o n t e x t[ 2 1 ] :t h ec o s tp e rd a t ap o i n ti sd r a m a t i c a l l y
lower for the clinically-integrated trial, so given a fixed
research budget, this approach will result in more infor-
mation to help guide clinical practice.
Conclusions
We have demonstrated the feasibility of a clinically-inte-
grated randomized trial, an approach that allows trials
to be run at very low cost, with minimal disruption to
patients and clinicians. A fully powered version of a
radical prostatectomy trial is now underway. Due to
incomplete documentation of surgical approach we
report here, the follow-up trial includes specific proce-
dures to aid documentation, by incorporating “tick
boxes” in the surgical medical record. We encourage
other researchers to consider how our methodology
might be applied to different research questions.
Additional material
Additional file 1: Appendix A 09 051 write up description of
surgical techniques. Detailed description, including diagrams, of the
surgical techniques compared in the trial.
Additional file 2: Appendix B 09 051 write up informed consent.
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Additional file 3: Appendix C 09 051 write up brief for clinical staff.
A briefing document circulated to clinical staff in urology that describes
the trial.
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